Skip to main content
Equibles

LOS ANGELES CAPITAL MANAGEMENT LLC

Position in EDIT — Editas Medicine, Inc.

CIK 1177206 LOS ANGELES, CA
Back to EDIT Full portfolio

Position in EDIT

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$878,642
+$531,785 QoQ
Shares Held
271,186
+93.1% QoQ
Ownership
0.177%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#43
of 216 holders
Holding Since
Mar 2020
21 quarters on record
Voting authority Sole 53% Shared 0% None 47%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,466,927 across 167 Biotechnology names. EDIT ranks #40 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 729,635 $219,642,024
2 HALO
Halozyme Therapeutics, Inc.
 1,938,035 $151,689,999
3 CAI
Caris Life Sciences, Inc.
 3,958,531 $70,541,022
4 INCY
Incyte Corp
 578,986 $65,633,852
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 130,802 $64,973,277
6 EXEL
Exelixis, Inc.
 1,159,457 $63,086,055
7 REGN
Regeneron Pharmaceuticals, Inc.
 98,585 $61,471,690
8 RPRX
Royalty Pharma plc
 877,674 $49,211,181

All Filings in EDIT

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $878,642 271,186
2026-03-31 $346,857 140,428
2025-12-31 $200,496 97,803
2025-09-30 $408,335 117,676
2025-06-30 $299,123 135,965
2025-03-31 $188,070 162,130
2024-12-31 $125,525 98,839
2024-09-30 $401,148 117,639
2024-06-30 $611,531 130,949
2024-03-31 $1,097,291 147,883
2022-09-30 $446,184 36,453
2022-06-30 $426,660 36,066
2022-03-31 $606,528 31,889
2021-12-31 $428,623 16,144
2021-09-30 $670,055 16,311
2021-06-30 $923,855 16,311
2021-03-31 $850,542 20,251
2020-12-31 $2,723,913 38,852
2020-09-30 $1,280,714 45,642
2020-06-30 $1,760,956 59,532
2020-03-31 $1,241,397 62,602